LuciNera Neratinib Tablets

I. Drug Name

Generic Name: Neratinib Maleate Tablets

Brand Names: Nerlynx, Heli'an, LuciNera

Dosage Form: Oral Tablets

Specification: 40 mg per tablet; 180 tablets per box

Manufacturer: Lucius Pharmaceutical (Laos) Co., Ltd.

Registration Number (Lao National Drug Administration): 10L1225/24

II. Indications and Usage

This product is an irreversible pan-HER tyrosine kinase inhibitor, indicated for:

1.  Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: Indicated for adult patients within one year of completing adjuvant trastuzumab-based therapy, to reduce the risk of recurrence.

2.  Advanced or Metastatic HER2-Positive Breast Cancer: In combination with capecitabine, indicated for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens.

III. Dosage and Administration

Recommended Dosage:

Early-Stage Breast Cancer (Monotherapy): 240 mg (i.e., six 40 mg tablets) orally once daily, taken continuously for one year.

Metastatic Breast Cancer (in Combination with Capecitabine): 240 mg orally once daily, taken on Days 1 through 21 of each 21-day cycle; the recommended dosage for capecitabine is 750 mg/m² orally twice daily, taken on Days 1 through 14 of each cycle.

Administration: Take with food. Tablets should be swallowed whole; do not crush, chew, or split the tablets.

Prophylactic Antidiarrheal Regimen: Crucial! Prophylaxis with loperamide (Imodium) must be initiated concurrently with the first dose of neratinib. The standard regimen is: During the first treatment cycle (56 days)—Days 1 through 14: 4 mg orally four times daily; Days 15 through 56: 4 mg orally twice daily. Thereafter, loperamide may be continued as needed to control diarrhea. **Dosage Adjustment:** Depending on the severity and duration of adverse reactions (such as diarrhea), measures such as temporarily withholding the drug, or reducing the dose to 200 mg, 160 mg, or 120 mg may be implemented.

**IV. Contraindications**

Patients with hypersensitivity to neratinib or to any of the excipients.

**V. Warnings and Precautions**

**1. Diarrhea:**

Diarrhea occurs in almost all patients, with a severe diarrhea incidence rate of up to 40%. It may occur early in the course of treatment (median time to onset is Day 8) and can lead to dehydration, electrolyte imbalances, and renal impairment.

Prevention, monitoring, and early aggressive intervention must be implemented in accordance with guidelines (including the use of loperamide, hydration, electrolyte replacement, and—if necessary—the use of other antidiarrheal agents or the temporary withholding/dose reduction of neratinib).

**2. Hepatotoxicity:**

Neratinib may cause elevations in liver transaminases. Liver function should be monitored regularly (e.g., monthly) prior to and during treatment. In cases of severe liver injury, the drug must be temporarily withheld, the dose reduced, or treatment permanently discontinued.

**3. Embryo-Fetal Toxicity:**

Neratinib may cause harm to the fetus. The pregnancy status of women of reproductive potential must be verified prior to initiating treatment. Patients must use effective non-hormonal methods of contraception during treatment and for at least 1 month following the last dose (as neratinib may reduce the efficacy of hormonal contraceptives).

**VI. Adverse Reactions**

**Very Common (>20%) and Major Adverse Reactions:**

**Gastrointestinal:** Diarrhea (incidence >90%), nausea, abdominal pain, vomiting, decreased appetite, dyspepsia.

**Skin and Subcutaneous Tissue:** Rash, dermatitis.

**Systemic Reactions:** Fatigue.

**Musculoskeletal:** Muscle spasms.

**Hepatic:** Elevated transaminases.

**Other:** Dry mouth, weight loss.

**Common Severe Adverse Reactions:** Diarrhea, vomiting, nausea, dehydration, acute kidney injury.

**VII. Drug Interactions**

**Proton Pump Inhibitors (PPIs, e.g., omeprazole), H2 Receptor Antagonists, and Antacids:** These agents significantly reduce the plasma concentration of neratinib, thereby reducing its efficacy. Concomitant use should be avoided. It is recommended to take Neratinib at least 3 hours before or at least 3 hours after taking antacids.

Strong or Moderate CYP3A4 Inducers (e.g., Rifampin, Phenytoin, Carbamazepine, St. John's Wort): These agents can significantly reduce Neratinib plasma concentrations; co-administration should be avoided.

Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Clarithromycin): These agents may increase Neratinib exposure, thereby increasing the risk of adverse reactions. Close monitoring is required during co-administration, and a reduction in the Neratinib dosage may be considered.

P-gp Substrates (e.g., Digoxin): Neratinib may increase the plasma concentrations of these agents; therefore, Digoxin plasma concentrations should be monitored during co-administration.

VIII. Use in Specific Populations

Hepatic Impairment: No dosage adjustment is required for patients with mild hepatic impairment. For patients with moderate hepatic impairment, the dosage should be reduced to 160 mg. Use should be avoided in patients with severe hepatic impairment.

Renal Impairment: No dosage adjustment is required for patients with mild to moderate renal impairment. Data are limited for patients with severe renal impairment or end-stage renal disease; therefore, the drug should be used with caution in these populations.

Pediatric Use: The safety and efficacy of Neratinib in pediatric patients have not been established.

Geriatric Use: No specific adjustment to the starting dosage is required; however, elderly patients may have lower tolerance for diarrhea and require close monitoring.

IX. Pharmacological Actions

Pharmacological Class: Irreversible pan-HER tyrosine kinase inhibitor.

Mechanism of Action: Neratinib covalently binds to the kinase domains of HER1 (EGFR), HER2, and HER4, thereby irreversibly inhibiting their kinase activity and blocking downstream signal transduction, which ultimately inhibits tumor cell proliferation and growth. In the context of early-stage breast cancer, its primary role lies in eradicating potential microscopic residual disease.

X. Storage

Store at room temperature (20°C to 25°C).

Keep the medication in its original packaging to protect it from moisture.

Keep out of the reach of children.

Important Note:

This package insert is not a substitute for professional medical advice. Prior to initiating treatment with neratinib, patients must undergo a comprehensive evaluation by a specialist and strictly adhere to the detailed medication instructions provided by their physician and pharmacist. Prophylactic and comprehensive management of diarrhea is central to the safe use of this medication. Regular monitoring and follow-up are mandatory throughout the course of treatment.